PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Levomepromazine hydrochloride - Nausea and vomiting (chemotherapy induced)
PAD Profile : Levomepromazine hydrochloride - Nausea and vomiting (chemotherapy induced)
Traffic Light Status
Status 1 of 2.
Status :
Red
Important
Formulations :
- Tablets
Important Information :
6mg or 6.25mg tablets for chemo-related nausea and vomiting.
ASPH restricted use - 6mg tablets for paediatric oncology only
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
No guidelines returned.
Other Drugs
- Palonosetron with netupitant
- Nabilone
- Cyclizine hydrochloride
- Dexamethasone
- Domperidone
- Metoclopramide hydrochloride
- Ondansetron hydrochloride
- Olanzapine
- Haloperidol
- Prochlorperazine maleate
- Aprepitant
- Fosaprepitant
- Granisetron
- Palonosetron hydrochloride
- Netupitant/palonosetron hydrochloride
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 November 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
Associated BNF Codes
04. Central Nervous System
04.06.00. Drugs used in nausea and vertigo